Levi & Korsinsky notifies investors that it has commenced an investigation into PROCEPT BioRobotics Corporation (NASDAQ: PRCT) concerning potential violations of the federal securities laws.
On the Q3 2025 earnings call on November 4, 2025, CFO Kevin Waters reaffirmed the $325.5 million revenue target and stated the company was "maintaining handpiece average selling prices to be approximately $3,200." CEO Larry Wood added that investments in strategic priorities were "not expect[ed] ... to impede our progress toward achieving profitability." At the time of these statements, the Company had implemented a pricing-discipline initiative that eliminated historical bulk-purchase discounts -- a change that directly reduced realized average selling prices on the Company's core product line. The guidance did not quantify or disclose the revenue impact of this pricing change. When Q4 2025 results were released, actual revenue fell $17.4 million short of the guided figure, and FY 2026 guidance of $410 million to $430 million also came in below analyst consensus. The stock lost roughly 15% of its value in a single session.
If you suffered a loss on your PROCEPT BioRobotics Corporation securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





